A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Trial Profile

A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 03 Oct 2017 Results (n=4464) of exploratory analysis assessing psychiatric adverse events occurrence across late stage brodalumab patients using patient data from NCT00975637, NCT01101100, NCT01708590, NCT01708603 and NCT01708629 trials and their open label extensions published in the Journal of the American Academy of Dermatology
    • 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Mar 2015 According to an Amgen media release, data from this study were presented at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top